News|Slideshows|March 7, 2019

Direct-Acting Antivirals Not Linked to Liver Cancer Recurrence

Results of the largest study of its kind may help quell longstanding controversy surrounding the impact of DAA therapy on recurrence of HCC.

In an effort to help clarify ongoingÂ controversy surrounding the effects of direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) infection on hepatocellular carcinoma (HCC) recurrence, researchers led by Amit G. Singal, MD, MS, conducted the largest study of its kind comparing HCC recurrence patterns between DAA-treated patients vs untreated patients across multiple clinical centers in the US and Canada. What did the study reveal? And how will the results impact clinical practice? Find out with our quick slideshow below.Â

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Latest CME

Virtual Event

Medical Crossfire®: BPDCN in 2026—Expert Perspectives on Diagnosis, Frontline Therapy, and the Evolving CD123-Directed Pipeline

July 21, 2026

Virtual Event

A Community-Based Roadmap to CAR-T Therapy: Optimizing Delivery and Outcomes

Webinar Series

$(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York$

Direct-Acting Antivirals Not Linked to Liver Cancer Recurrence

Related Content

FDA Accepts Cefiderocol sNDA for Pediatric Gram-Negative Infections

7 Drugs Approved for Primary Care: Q2 2026

FDA Clears First Generic Baloxavir for Influenza Treatment, Postexposure Prophylaxis

Cognitive Rehabilitation Linked to Functional Gains in Long COVID Trial

Survey Finds Gaps in US Adult Awareness of HPV, Mpox STI Vaccine Prevention

Latest CME

Medical Crossfire®: BPDCN in 2026—Expert Perspectives on Diagnosis, Frontline Therapy, and the Evolving CD123-Directed Pipeline

A Community-Based Roadmap to CAR-T Therapy: Optimizing Delivery and Outcomes

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

Rhode Island Oncology Society

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

27th Annual International Lung Cancer Congress®

Castleman Disease in Practice—Recognizing, Classifying, and Treating a Rare Disorder

Project ECHO®: Advancing Care in Metastatic TNBC Through PD-L1–Informed Novel Frontline ADC Strategies

PER Global Perspectives: Preparing for the Emergence of TROP2 ADCs With Immunotherapy in the Earlier Treatment Settings

PER Global Perspectives: Differentiating and Managing Toxicities with TROP2-Targeted ADCs in NSCLC Through Multidisciplinary Pathways

Burst CME: Managing Fluid Overload in Patients with Chronic Kidney Disease (Part 1)

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Looking Beneath the Surface: Latest Updates in Identifying and Managing Hypercortisolism in Patients with Type 2 Diabetes

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Community Practice Connections™: 16th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Tennessee

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Washington

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Kansas Society of Clinical Oncology

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Montana/Wyoming

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – North Carolina

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Burst CME: Managing Fluid Overload in Patients with Chronic Kidney Disease (Part 2)

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Kansas Society of Clinical Oncology

Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management

Optimizing Treatment for Biliary Tract Cancers

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Cross-Disease Integration of Immunotherapy Innovations

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Arizona Clinical Oncology Society

Nevada Oncology Society

Missouri Oncology Society

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Tackling Barriers to Vaccine Uptake: Practical Strategies for Adult Immunization

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Burst CME CGM: Continuous Glucose Monitoring Considerations – Maximizing Quality of Life for Patients

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Cases and Conversations™: Mineralocorticoid Receptor Antagonists in Patients With HF—Augmenting Current Guidelines with Emerging Evidence

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

26th Annual International Lung Cancer Congress

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

IgAN Case Files: Real Conversations, Evolving Evidence

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Montana/Wyoming

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – North Carolina

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Washington

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Tennessee